CRCT research

 

On a daily basis, we are working to find the solutions of tomorrow!

18 teams of researchers are advancing knowledge on the mechanisms of cancer onset and progression, and contributing to improving screening, care and management of patients in order to better support them on their way to recovery.

The 4 axis Of
Specific research

Oncogenic pathways in cancer: From modelization towards targeted therapy

The objective is to federate researchers, clinicians, engineers, technicians and students of the CRCT in order to share a multidisciplinary expertise with the common goal of understanding and targeting autonomous and non-autonomous mechanisms of cancer oncogenic pathways.
+

RNA & CANCER

CRCT researchers are exploring the mechanisms of deregulation of RNAs, key players in the control of gene expression, and their role in altering the cellular landscape that can lead to cancer initiation, progression, invasion and metastasis.

+

Tumour microenvironment and metabolism

The objective of this axis is to understand and identify targets in both tumour cells and stroma, the co-targeting of which could sensitiee tumours to therapies and/or abrogate their metastatic potential.

+

Onco-immunology

The aim of this axis is to promote collaboration between teams interested in studying the cancer/immune system confrontation through different but complementary approaches.

+

The TOUCAN LABEX

The Toulouse Cancer Laboratory of Excellence (LabEx TOUCAN) is a project that aims to understand the mechanisms of resistance and relapse in hematological cancers.

Funded by the Agence Nationale de la Recherche (ANR) under the Programme d’Investissements d’Avenir (PIA), it brings together six Toulouse research teams from the Toulouse Cancer Research Centre (CRCT) and the Institute of Pharmacology and Structural Biology (IPBS).

+

With institutional support

CHU

CHU

IUCT-O

IUCT-O

INSERM

INSERM

UNIVERSITE FEDERALE TOULOUSE

UNIVERSITE FEDERALE TOULOUSE

UT3

UT3

ICR

ICR

ANR

ANR

Plan Investissement

Plan Investissement

FONDATION TOULOUSE CANCER

FONDATION TOULOUSE CANCER

CNRS

CNRS

TRANSLATIONAL PROJECTS
AND EUROPEAN PROGRAMMES

TRANSLATIONAL RESEARCH PROJECTS @IUCT-O

Each year, the Toulouse-Oncopole University Cancer Institute and the Toulouse Cancer Health Foundation open an internal call for proposals to finance translational research projects led by a researcher/clinician pair.
The projects are evaluated by an external jury made up of experts in the themes submitted.

Find below all the winning projects since 2017.

MELANICa

To evaluate the potential benefit of anti-TNF on the anti-cancer immune response in melanoma patients.

+
MMIL

To better understand the mechanisms of recognition and eradication of cancer cells by the immune system.

+
CIEL

Immune escape and innate immunity in lymphoma

+
LMSTAR
To treat leiomyosarcoma by targeting the SRF?
+
ONCOPOLE

Functional analysis of the inherited N363K POLE mutation in highly aggressive colon cancers and glioblastomas

+
LUNG-RESIST

Targeting the early stages of adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancer.

+
EPOXAN

Characterisation of deregulations of the cholesterol-epoxide pathway in breast cancer

CLUSTER

Clustering of malignant cells in serous fluid: a mechanism of tumour progression?

+
GAMER
Genomic abnormalities in early myeloma relapse
+
Comm’in BC

Cellular communication in breast cancer

+
DEMETEAR

Deciphering mechanisms of resistance to targeted therapies in B-cell chronic lymphocytic leukemia

+

OTHER RESEARCH PROGRAMMES

Researchers are encouraged and guided in their participation in the various calls for proposals from biomedical research funders (INCA, ANR, patient associations, etc.)

The CRCT researchers are fully involved in these calls for proposals. Find below all the programmes in which the CRCT is strongly involved.

INTERPEDIA

Deciphering patient’s hematologic phenotype with GATA2 mutation with new meaningful models to better understand the risk of leukemia and time to bone marrow transplantation

+

EUROPEAN PROGRAMMES

Biomedical research is strongly embedded in the European context. Researchers are encouraged and guided in their participation in the various Horizon 2020 programmes, the main instrument for implementing European research.

The CRCT researchers are fully involved in these calls for projects. Find below all the European programmes in which the CRCT is strongly involved.

PROTEOblood

Development of new therapies against two subtypes of lymphoma and leukaemia.

+
MITHAML

Metabolic heterogeneity in acute myeloid leukaemia

+
IMMUSPHINX

Targeting sphingolipid metabolism to improve the efficacy of immunotherapies in melanoma.

+
PINICAL-MRT

Clinical impact protocols in molecular radiotherapy

+
MEDIRAD

Consequences of medical exposure to low-dose radiation

+
IMLINFO

Cross-border network of personalised immunotherapies for non-Hodgkin’s lymphoma

+
ALKATRAS

Role and regulation of autophagy in ALK dependent tumours

+
PIPgen

a new Innovative Training Network to put PI3K/PTEN related diseases under the spotlight

+

18 RESEARCH

TEAMS

Team

Maha AYYOUB

T2i : Anti-tumour immunity and immunotherapy

+

Team

Gilles FAVRE and Olivier SORDET

SIGNATHER : Cell Signalling, Oncogenesis and Therapeutics

+

Team

Bruno SEGUI and Nathalie ANDRIEU

MELASPHINX : Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy

+

Team

Stefania MILLEVOI

RNAreg : RNA-Binding Proteins and Genotoxic Stress

+

Team

Corinne BOUSQUET

MICROPANC : Microenvironnement and Therapeutic Resistance in Pancreatic Neoplasms

 

 

+

Team

Stéphane PYRONNET
and Fabienne MEGGETTO

R’n Blood : RNA Biology in Hematologic Tumors

+

Team

Camille Laurent

NoLymIT : New Immunotherapies Against Lymphoma

+

Team

Pierre Cordelier

ImPACT : Innovation in pancreatic cancer therapy

+

Team

Elizabeth
COHEN-JONATHAN MOYAL

RADOPT : Optimising radiotherapy: from molecular signalling pathways to clinical trials

+

Team

Marc POIROT and Sandrine SILVENTE-POIROT

INOV : Cholesterol Metabolism and Therapeutic Innovations

+

Team

Hervé AVET-LOISEAU
and LUDOVIC MARTINET

GENIM : Genomic and Immunology of myeloma

+

Team

Etienne CHATELUT

DIAD : Dose Individualisation of Anticancer Drugs

+

Team

Eric DELABESSE

IGAALD : Impact of genetic alterations on acute leukemia development

+

Team

Julie GUILLERMET-GUIBERT

SigDYN : Integrated cellular signalling and PI3K isoforms

+

Team

Jean Emmanuel SARRY

METAML : Metabolism and Therapeutic Resistance In Acute Myeloid Leukemia

+

Team

Frédéric CHIBON

ONCOSARC – Oncogenesis of sarcomas

+

Team

Salvatore VALITUTTI

DynAct : Molecular dynamics of Lymphocyte Interactions

+

Team

Véra PANCALDI

NetB(IO)² : Network Biology for Immuno-oncology

 

+
Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches en Cancérologie de Toulouse (Oncopole)

Toulouse – FR

Nous contacter

05 82 74 15 75

Envie de rejoindre
L’équipe du CRCT ?

Pin It on Pinterest